ABSTRACT
Background: Polycystic ovarian syndrome, commonly known as PCOs. It is the most common endocrine disorder in women involving cyst formation on ovaries which eventually affects the hormonal imbalance and is now well evidenced with obesity, insulin resistance, hyperandrogenism, abnormal lipid profile and oxidation stress.
Subjects and methods: This prospective comparative & interventional study evaluated QOL & effect of CoQ10 in PCOs patients.
Results: Out of 40 patients,30 are married and 10 are unmarried.8 are between 18-22years,13 are between 21-23 years,7 are between 24-26 years,7 are between 27-29 years,3 are between 30-32 years,2 are between 33-35 years.32 are having Irregular menses as major complaint & 8 are having An ovulation as major complaint.20 are between 1-2years of onset of disease,3 are between 2-3 years of onset of disease,7 are between 3-4 years of onset of disease and7 are between 4-5 years of onset of disease.13 are tested with PCOS between 18-22years,9 between 23-27 years,3 between 28-32years & 2 between 33 & above years.10 are suffering from PCOS between 18-22 years,5 are between 23-27 years,2 are between 28-32 years, 2 are between 33 & above years.8 women are aware of infertility due to PCOS between 18-22 years, 3 are between 23-27 years,5 are between 27-32 years,2 are between 33 & above years.
Conclusion: The present study revealed that majority of women was aware of PCOS. A few of them already tested themselves for PCOs.CoQ-10 was well tolerated by all the patients and no adverse effects were observed. The lack of any statistically significant differences in the ovulation and clinical pregnancy rates between lean and obese PCOS in the CoQ-10 group suggests that response to CoQ-10 group is independent of body weight, contrary to other methods of ovulation induction.
Keywords: Anovulation, Quality of Life, Irregular menses, Clomiphene citrate, CoQ-10 (Co-enzyme Q-10), Antioxidants, PCO.